Barchas Isaac 4

What Happened
Isaac Barchas, a director of Immunome Inc. (IMNM), sold a total of 100,000 shares in two open-market transactions: 83,094 shares on 2026-07-06 at a weighted-average price of $24.11 for proceeds of $2,003,396, and 16,906 shares on 2026-07-07 at a weighted-average price of $24.20 for proceeds of $409,125. Total proceeds were approximately $2,412,521. These were sales (not purchases) and therefore are typically considered routine liquidity rather than a direct bullish signal.

Key Details

• Transaction dates and amounts:
  • 2026-07-06: 83,094 shares sold; weighted avg. price $24.11; proceeds $2,003,396. Price range reported: $24.00–$24.29. (Footnote: full per-price breakdown available on request.)
  • 2026-07-07: 16,906 shares sold; weighted avg. price $24.20; proceeds $409,125. Price range reported: $24.00–$24.58. (Footnote: full per-price breakdown available on request.)
• Plan/authorization: Sales were made automatically under a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (referred to as ABHMC) on March 31, 2026.
• Ownership/beneficial interest: ABHMC owns the shares sold; Barchas is a managing member with power of attorney over those shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
• Filing timeliness: Report filed 2026-07-07 for transactions on 2026-07-06 and 2026-07-07 — appears to be timely.
• Shares owned after transaction: Not disclosed in the provided filing.

Context
Because these sales were executed under a Rule 10b5-1 plan and by an entity (ABHMC) that holds the shares, they were likely pre-scheduled and should not be taken alone as a statement about the company’s near-term prospects. For retail investors, purchases typically carry more direct informational weight than routine sales; here the filing documents institutional/plan-driven sales rather than an immediate exercise-and-sell or gift.